« Back
AVI BioPharma, Inc. Presenting at BMO Focus on Healthcare Conference
07/29/09 2:14 PM EDT
For Immediate Release
CORVALLIS, OR — July 29, 2009 — AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Leslie Hudson, Ph.D., President and Chief Executive Officer, will present at the BMO Capital Markets 9th Annual Focus on Healthcare Conference taking place Wednesday, August 5, 2009 in New York.
Dr. Hudson will present at 4 p.m. Eastern Time. A live and archived webcast of the presentation will be accessible at: http://www.bmocm.com/conferences/2009healthcare/webcast/ and can also be accessed by visiting the "Events and Presentations" section of the AVI BioPharma website www.avibio.com .
About AVI BioPharma
AVI BioPharma is focused on the discovery and development of RNA-based drugs utilizing proprietary derivatives of its antisense chemistry (morpholino-modified phosphorodiamidate oligomers or PMOs) that can be applied to a wide range of diseases and genetic disorders through several distinct mechanisms of action. Unlike other RNA-based therapeutic approaches, AVI's antisense technology has been used to directly target both messenger RNA (mRNA) and its precursor (pre-mRNA), allowing for both up- and down-regulation of targeted genes and proteins. AVI's RNA-based drug programs are being evaluated for the treatment of Duchenne muscular dystrophy as well as for the treatment of cardiovascular restenosis through our partner Global Therapeutics, a Cook Group Company. AVI's antiviral programs have demonstrated promising outcomes in Ebola Zaire and Marburg Musoke virus infections and may prove applicable to other viral targets such as HCV or Dengue viruses. For more information, visit www.avibio.com.
This section of our website may contain dated or archived information which should not be considered current and may no longer be accurate. For current information, you are encouraged to review our most recent official corporate documents on file with the U.S. Securities and Exchange Commission.